99.73
+3.49(+3.63%)
Currency In USD
| Previous Close | 96.24 |
| Open | 96.79 |
| Day High | 102.45 |
| Day Low | 95.96 |
| 52-Week High | 112 |
| 52-Week Low | 11.17 |
| Volume | 966,435 |
| Average Volume | 243,174 |
| Market Cap | 1.18B |
| PE | -34.15 |
| EPS | -2.92 |
| Moving Average 50 Days | 85.2 |
| Moving Average 200 Days | 47.56 |
| Change | 3.49 |
If you invested $1000 in Palvella Therapeutics, Inc. (PVLA) since IPO date, it would be worth $5,866.47 as of December 22, 2025 at a share price of $99.73. Whereas If you bought $1000 worth of Palvella Therapeutics, Inc. (PVLA) shares 1 year ago, it would be worth $5,866.47 as of December 22, 2025 at a share price of $99.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
GlobeNewswire Inc.
Dec 16, 2025 12:30 PM GMT
Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN™ rapamycin for angiokeratomas may be eligible for Accelerated Appr
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies
GlobeNewswire Inc.
Dec 15, 2025 11:00 AM GMT
73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2) or “Very M
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2025 12:30 PM GMT
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering f